PhaseV Unveils AI/ML Tools for Clinical Trial Design at CMO Summit

PhaseV will showcase its new AI/ML-powered clinical trial design and analysis capabilities at the CMO Summit 360° in Boston, enhancing trial success prediction and planning.

PhaseV announced in a press release that it will showcase its latest AI/ML-powered capabilities for clinical trial design and analysis at the upcoming Chief Medical Officer (CMO) Summit 360° in Boston. The new tools are designed to integrate insights from previous clinical trials into future study designs, enhancing decision-making and improving patient outcomes.

The platform's Causal to Adaptive capability allows clinical teams to leverage causal machine learning-driven insights from prior trials and real-world data. This integration aims to improve planning, efficiency, and decision-making for future clinical trials. Additionally, the Clinical Trial Success Prediction tool quantifies the probability of success by analyzing historical trial data and real-world evidence, supporting more informed decision-making and reducing failure rates.

Live demonstrations of these capabilities will be conducted at the CMO Summit 360° in Boston from April 7-8, providing attendees with an opportunity to see the platform's potential in action.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.

Also, consider following our LinkedIn page AI Brief.

More from: Healthcare & Life Sciences

Subscribe to Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates

You May Also Like